BioWorld

Jan. 28, 2002

AltaRex Plans U.S. Filing Despite Mixed Results Of OvaRex Trials

Despite inconsistent results in Phase IIb trials, Canadian company AltaRex Corp. intends this year to file a rolling biologics license application for its late-stage ovarian cancer drug, OvaRex. Read More

Trimeris Raising $41M Privately As It Eyes NDA For HIV Drug

Hunt For Signs Of Life On Mars Gets Boost From Live Archaea Deep Under Idaho Hot Springs

Intradigm, DirectGene Team Up To Develop Cancer Therapeutics

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...